Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Bacillus clausii is a spore-forming probiotic bacteria that produces antimicrobial peptides and organic acids to restore gut microbiome balance. It works by competing with pathogenic bacteria for colonization sites while enhancing intestinal barrier function through tight junction protein regulation.
Reported Benefits (Provisional)
Origin & History
Bacillus clausii is a spore-forming probiotic bacterium that is naturally found in soil and water. It is produced through fermentation and used in various probiotic supplements to support digestive health.
Research Narrative (Provisional)
Research on Bacillus clausii includes randomized controlled trials (RCTs) demonstrating its efficacy in reducing the duration of diarrhea and supporting gut health. Meta-analyses also support its use in restoring intestinal flora balance.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Bacillus clausii (Enterogermina) is a spore-forming probiotic bacterium with negligible direct macronutrient contribution at therapeutic doses (typically 2×10⁹ spores per 5mL vial). Macronutrient content per standard dose: protein <0.01g, carbohydrates <0.01g, fat <0.01g, calories ~0 kcal. The primary bioactive components are the bacterial spores themselves and their metabolic byproducts. Key bioactive compounds include: (1) Bacteriocin-like inhibitory substances (BLIS) that suppress pathogenic bacteria; (2) Short-chain fatty acids (SCFAs) produced during fermentation, particularly butyrate, acetate, and propionate, which fuel colonocyte health; (3) Biosurfactants with antimicrobial properties; (4) Exopolysaccharides (EPS) that modulate mucosal immunity. B. clausii strains (O/C, N/R, T, SIN) are known to synthesize B-group vitamins including riboflavin (B2, ~0.3–0.8 µg per 10⁹ spores), folic acid (B9, trace levels ~0.1–0.2 µg per 10⁹ spores), and pyridoxine (B6, trace). Antibiotic-resistance genes in specific strains allow survival alongside antibiotic therapy. Bioavailability note: spores resist gastric acid (stable at pH 2–3) and bile salts, achieving >85% intestinal delivery efficiency, where they germinate into vegetative cells and exert metabolic activity. No significant dietary fiber, minerals, or fat-soluble vitamins are contributed at standard dosing.
Reported Mechanism (Provisional)
Bacillus clausii produces bacteriocins and organic acids that inhibit pathogenic bacterial growth while promoting beneficial microflora colonization. The strain enhances intestinal barrier integrity by upregulating claudin-1 and occludin tight junction proteins. It also stimulates secretory IgA production through interaction with Peyer's patches and dendritic cells in gut-associated lymphoid tissue.
Clinical Narrative (Provisional)
Clinical trials demonstrate Bacillus clausii reduces IBS symptom severity by up to 50% in studies involving 200+ participants over 8-12 week periods. Randomized controlled trials show significant improvements in stool consistency and abdominal pain scores compared to placebo. Multiple studies confirm its effectiveness in preventing antibiotic-associated diarrhea, with success rates of 70-80%. However, most trials are relatively small-scale and additional large-scale studies would strengthen the evidence base.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.